West Pharmaceutical Services, Inc. (WST)
Automate Your Wheel Strategy on WST
With Tiblio's Option Bot, you can configure your own wheel strategy including WST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WST
- Rev/Share 41.7317
- Book/Share 42.2061
- PB 5.472
- Debt/Equity 0.0993
- CurrentRatio 2.8695
- ROIC 0.144
- MktCap 16615331001.0
- FreeCF/Share 5.2434
- PFCF 43.8284
- PE 33.9591
- Debt/Assets 0.0738
- DivYield 0.0037
- ROE 0.1733
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WST | Morgan Stanley | -- | Equal Weight | -- | $285 | Dec. 2, 2025 |
| Initiation | WST | Rothschild & Co Redburn | -- | Buy | -- | $311 | Sept. 15, 2025 |
| Initiation | WST | Barclays | -- | Equal Weight | -- | $245 | June 24, 2025 |
| Initiation | WST | Evercore ISI | -- | Outperform | -- | $275 | March 18, 2025 |
| Upgrade | WST | Deutsche Bank | Hold | Buy | -- | $250 | Feb. 14, 2025 |
| Initiation | WST | Citigroup | -- | Buy | -- | $400 | Jan. 8, 2025 |
| Initiation | WST | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Upgrade | WST | UBS | Neutral | Buy | $350 | $390 | Dec. 12, 2024 |
News
Here's Why West Pharmaceutical (WST) Is a Great 'Buy the Bottom' Stock Now
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical (WST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
COO vs. WST: Which Stock Should Value Investors Buy Now?
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
Read More
Time To Buy The Dip In West Pharmaceutical Stock?
Published: January 26, 2026 by: Forbes
Sentiment: Positive
West Pharmaceutical Services (WST) stock should be included in your watchlist. Here's why – it is currently operating within the support zone ($224.83 – $248.49), prices from which it has previously bounced significantly.
Read More
WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support.
Read More
All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
4 Medical Supply Stocks Poised to Gain in a Prospering Industry
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and ALGN.
Read More
Best Income Stocks to Buy for January 22nd
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
GES, PAA and WST made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 22, 2026.
Read More
After Plunging 9.7% in 4 Weeks, Here's Why the Trend Might Reverse for West Pharmaceutical (WST)
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for West Pharmaceutical (WST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 14, 2026 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Negative
WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook.
Read More
Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
COO or WST: Which Is the Better Value Stock Right Now?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either The Cooper Companies (COO) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
Read More
West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. ( WST ) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief Proprietary Segment Officer John Sweeney - Head of Investor Relations Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division Welcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst.
Read More
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. ( WST ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Robert McMahon - Senior VP & CFO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research.
Read More
West Pharmaceutical Services, Inc. (WST) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. ( WST ) UBS Global Healthcare Conference 2025 November 11, 2025 9:30 AM EST Company Participants Robert McMahon - Senior VP & CFO Presentation Unknown Analyst Joining our next session is with West Pharma and joining me on stage from West is Bob McMahon. Well, Bob.
Read More
West Pharmaceutical Services, Inc. (WST) Q3 2025 Earnings Call Transcript
Published: October 23, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants John Sweeney - Head of Investor Relations Eric Green - Non-Independent Chair of the Board, President & CEO Robert McMahon - Senior VP & CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Michael Ryskin - BofA Securities, Research Division Patrick Donnelly - Citigroup Inc., Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Daniel Leonard - UBS Investment Bank, Research Division Justin Bowers - Deutsche Bank AG, Research Division Lawrence Solow - CJS Securities, Inc. …
Read More
WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.
Read More
West Pharmaceutical Services: HVP Moat Cum GLP-1 And Biologics Tailwinds Reinforce Upward Momentum
Published: October 21, 2025 by: Seeking Alpha
Sentiment: Positive
West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin growth through proprietary, high-margin offerings and regulatory stickiness. Surging demand for GLP-1 therapies and biologics underpins durable growth for WST's containment and delivery systems, reinforcing the investment thesis.
Read More
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
Read More
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Negative
WST's growth prospects remain strong, fueled by GLP-1 demand and high-value products, though tariffs and execution risks weigh on margins.
Read More
WEST PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In West Pharmaceuticals (WST) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in West between February 16, 2023 to February 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
West Pharmaceutical Services, Inc. (NYSE:WST ) Bank of America Global Healthcare Conference 2025 September 24, 2025 10:05 AM EDT Company Participants Eric Green - Non-Independent Chair of the Board, President & CEO Robert McMahon - Senior VP & CFO Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division Thanks for joining us for our next session. My name is Mike Ryskin.
Read More
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Read More
Wall Street Analysts See a 28.68% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
West Pharmaceutical: Q2 Earnings Suggest Recovery
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Positive
West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs now provide a powerful, sustained growth catalyst beyond the company's traditional biologics and injectable therapeutics exposure. Risks include elevated valuation, potential competition, and the threat of oral GLP-1 formulations or healthcare policy changes impacting future growth.
Read More
Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About West Pharmaceutical Services, Inc. (WST)
- IPO Date 1980-03-17
- Website https://www.westpharma.com
- Industry Medical - Instruments & Supplies
- CEO Eric Green
- Employees 10600